Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis

Author： Zhang Xiaoping   Morcos Peter N   Saito Tomohisa   Terao Kimio  

Publisher： Informa Healthcare

ISSN： 1751-2433

Source： Expert Review of Clinical Pharmacology, Vol.6, Iss.2, 2013-03, pp. : 123-137

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tocilizumab takes control of juvenile idiopathic arthritis

By  

Inpharma, Vol. 1, Iss. 1632, 2008-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Tocilizumab reduces disease activity in patients with systemic-onset juvenile idiopathic rheumatoid arthritis

By  

Inpharma, Vol. 1, Iss. 1488, 2005-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Treatment strategies for juvenile idiopathic arthritis

By Klein Ariane   Horneff Gerd  

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 18, 2009-12 ,pp. : 3049-3060

Informa Healthcare

Access to resources Recommend Favorite

Novel therapies for the treatment of juvenile rheumatoid arthritis (juvenile idiopathic arthritis)

By Agle Lucila MA   Rosenkranz Margalit   Lehman Thomas JA  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 1, 2003-01 ,pp. : 19-28

Informa Healthcare

Access to resources Recommend Favorite

Juvenile idiopathic arthritis: current and future treatment options

By Martini Giorgia   Zulian Francesco  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 4, 2006-03 ,pp. : 387-399

Informa Healthcare

Access to resources Recommend Favorite